HUMANIZING ANTIBODIES

With 20 years experience we can deliver your
humanized antibody in just 6 months

Our Therapeutic Antibody Group (TAG) offers you the ability to take advantage of its substantial know-how to target major life-threatening and debilitating diseases. With the need to quickly and effectively develop drugs, our expertise in antibody humanization can rapidly progress your therapeutic antibody candidates.

Antibody humanization is a rapid and reliable developmental process which offers:

• Short Clinical development times
• High regulatory approval rates
• Better management of risk

Today, antibody humanization is a clinically validated technology with nine humanized antibodies already on the market and another 75 or more in clinical trials. It is the dominant technology currently being exploited by pharmaceutical companies for the development of therapeutic antibodies.

In 2007 therapeutic antibodies produced revenues well in excess of US$25 billion, around 50% of which was generated by humanized antibodies. Between 2006 and 2012, revenue for therapeutic antibodies is forecast to grow by a CAGR of 14.2%.

For our latest Humanizing Antibodies brochure (PDF) please click here